Zenas BioPharma, Inc. (ZBIO) Stock

NASDAQ: ZBIOHealthcare company in the biotechnology industry, based in Waltham, MA.

Zenas BioPharma stock price chart

ZBIO interactive chart →

ZBIO stock quote & key statistics

Zenas BioPharma earnings per share

Income →
Earnings per share

Zenas BioPharma revenue & net income

Income →
RevenueNet income

Zenas BioPharma annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$10.0M-$377.7M-$4.66
FY2024$5.0M-$157.0M-$9.07
FY2023$50.0M-$37.1M—
FY2022$0-$119.3M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.

The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Zenas BioPharma stock FAQ

What is the Zenas BioPharma stock ticker symbol?

Zenas BioPharma, Inc. trades on the NASDAQ under the ticker symbol ZBIO.

What sector and industry is Zenas BioPharma in?

Zenas BioPharma, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Zenas BioPharma have?

Zenas BioPharma, Inc. has about 167 full-time employees.

What were Zenas BioPharma's revenue and earnings last fiscal year?

Zenas BioPharma reported revenue of $10.0M and net income of -$377.7M in fiscal 2025, with earnings per share of -$4.66. Revenue grew 100.0% from the prior year.

Is Zenas BioPharma in the Russell 2000?

Yes. Zenas BioPharma, Inc. (ZBIO) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Zenas BioPharma go public?

Zenas BioPharma stock began trading on September 13, 2024.

Russell 2000 Biotechnology stocks

All Russell 2000 →